239 related articles for article (PubMed ID: 24660725)
1. Patient compliance and diagnostic yield of 18-month unilateral follow-up in surveillance of probably benign mammographic lesions.
Chung CS; Giess CS; Gombos EC; Frost EP; Yeh ED; Raza S; Birdwell RL
AJR Am J Roentgenol; 2014 Apr; 202(4):922-7. PubMed ID: 24660725
[TBL] [Abstract][Full Text] [Related]
2. Imaging and Histopathologic Features of BI-RADS 3 Lesions Upgraded during Imaging Surveillance.
Michaels A; Chung CS; Birdwell RL; Frost EP; Giess CS
Breast J; 2017 Jan; 23(1):10-16. PubMed ID: 27612001
[TBL] [Abstract][Full Text] [Related]
3. Revisiting the mammographic follow-up of BI-RADS category 3 lesions.
Varas X; Leborgne JH; Leborgne F; Mezzera J; Jaumandreu S; Leborgne F
AJR Am J Roentgenol; 2002 Sep; 179(3):691-5. PubMed ID: 12185047
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of probably benign (BI-RADS 3) lesions in mammography: what is the right follow-up protocol?
Buch KA; Qureshi MM; Carpentier B; Cunningham DA; Stone M; Jaffe C; Quinn M; Gonzalez C; LaVoye J; Hines N; Bloch BN
Breast J; 2015; 21(2):168-74. PubMed ID: 25669425
[TBL] [Abstract][Full Text] [Related]
5. Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database.
Berg WA; Berg JM; Sickles EA; Burnside ES; Zuley ML; Rosenberg RD; Lee CS
Radiology; 2020 Jul; 296(1):32-41. PubMed ID: 32427557
[TBL] [Abstract][Full Text] [Related]
6. Reassessment and Follow-Up Results of BI-RADS Category 3 Lesions Detected on Screening Breast Ultrasound.
Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
AJR Am J Roentgenol; 2016 Mar; 206(3):666-72. PubMed ID: 26901026
[TBL] [Abstract][Full Text] [Related]
7. Characteristics, Malignancy Rate, and Follow-up of BI-RADS Category 3 Lesions Identified at Breast MR Imaging: Implications for MR Image Interpretation and Management.
Chikarmane SA; Birdwell RL; Poole PS; Sippo DA; Giess CS
Radiology; 2016 Sep; 280(3):707-15. PubMed ID: 27089027
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of unconventional utilization of BI-RADS category 3 assessment at opportunistic screening.
Altas H; Tureli D; Cengic I; Kucukkaya F; Aribal E; Kaya H
Acta Radiol; 2016 Nov; 57(11):1304-1309. PubMed ID: 26019241
[TBL] [Abstract][Full Text] [Related]
9. Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09-41.
Hooley RJ; Greenberg KL; Stackhouse RM; Geisel JL; Butler RS; Philpotts LE
Radiology; 2012 Oct; 265(1):59-69. PubMed ID: 22723501
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Malignancy and Imaging Characteristics of Probably Benign Lesions Seen at Breast MRI.
Grimm LJ; Anderson AL; Baker JA; Johnson KS; Walsh R; Yoon SC; Ghate SV
AJR Am J Roentgenol; 2015 Aug; 205(2):442-7. PubMed ID: 26204298
[TBL] [Abstract][Full Text] [Related]
11. Probably benign lesions at screening breast US in a population with elevated risk: prevalence and rate of malignancy in the ACRIN 6666 trial.
Barr RG; Zhang Z; Cormack JB; Mendelson EB; Berg WA
Radiology; 2013 Dec; 269(3):701-12. PubMed ID: 23962417
[TBL] [Abstract][Full Text] [Related]
12. Frequency and Cancer Yield of BI-RADS Category 3 Lesions Detected at High-Risk Screening Breast MRI.
Edmonds CE; Lamb LR; Mercaldo SF; Sippo DA; Burk KS; Lehman CD
AJR Am J Roentgenol; 2020 Feb; 214(2):240-248. PubMed ID: 31799867
[No Abstract] [Full Text] [Related]
13. Effectiveness of assigning BI-RADS category-3 to breast lesion with respect to follow-up.
Masroor I
J Coll Physicians Surg Pak; 2008 Apr; 18(4):209-12. PubMed ID: 18474152
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic mammography and sonography: concordance of the breast imaging reporting assessments and final clinical outcome].
Lorenzen J; Wedel AK; Lisboa BW; Löning T; Adam G
Rofo; 2005 Nov; 177(11):1545-51. PubMed ID: 16302136
[TBL] [Abstract][Full Text] [Related]
15. Is a one-year follow-up an efficient method for better management of MRI BI-RADS(®) 3 lesions?
Boisserie-Lacroix M; Ziadé C; Hurtevent-Labrot G; Ferron S; Brouste V; Lippa N
Breast; 2016 Jun; 27():1-7. PubMed ID: 27212693
[TBL] [Abstract][Full Text] [Related]
16. Interobserver variability in upgraded and non-upgraded BI-RADS 3 lesions.
Michaels AY; Chung CSW; Frost EP; Birdwell RL; Giess CS
Clin Radiol; 2017 Aug; 72(8):694.e1-694.e6. PubMed ID: 28381334
[TBL] [Abstract][Full Text] [Related]
17. Tomosynthesis in the Diagnostic Setting: Changing Rates of BI-RADS Final Assessment over Time.
Raghu M; Durand MA; Andrejeva L; Goehler A; Michalski MH; Geisel JL; Hooley RJ; Horvath LJ; Butler R; Forman HP; Philpotts LE
Radiology; 2016 Oct; 281(1):54-61. PubMed ID: 27139264
[TBL] [Abstract][Full Text] [Related]
18. Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions.
Pediconi F; Catalano C; Roselli A; Padula S; Altomari F; Moriconi E; Pronio AM; Kirchin MA; Passariello R
Radiology; 2007 Jun; 243(3):670-80. PubMed ID: 17446524
[TBL] [Abstract][Full Text] [Related]
19. A Single-Center Audit of BI-RADS 3 Assessment Category Utilization in Mammography and Breast Ultrasound.
Common J; Abdullah P; Alabousi A
Can Assoc Radiol J; 2023 Feb; 74(1):69-77. PubMed ID: 36041944
[No Abstract] [Full Text] [Related]
20. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications.
Cilotti A; Iacconi C; Marini C; Moretti M; Mazzotta D; Traino C; Naccarato AG; Piagneri V; Giaconi C; Bevilacqua G; Bartolozzi C
Radiol Med; 2007 Mar; 112(2):272-86. PubMed ID: 17361370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
